These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33336814)

  • 1. Epidermolysis bullosa pruriginosa treated with dupilumab.
    Zhou AG; Little AJ; Antaya RJ
    Pediatr Dermatol; 2021 Mar; 38(2):526-527. PubMed ID: 33336814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of epidermolysis bullosa pruriginosa by dupilumab.
    Wu XG; Yan S; Jiang JQ; Zhou TT; Fang X; Yang H; Bai XM; Wang H; Luo X
    J Dermatol; 2023 Jun; 50(6):837-842. PubMed ID: 36694424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.
    Yang DY; Jing WW; Liu X; Li L; Lu T; Li XL
    Adv Skin Wound Care; 2024 Feb; 37(2):1-4. PubMed ID: 38241457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin.
    Aala WJF; Hou PC; Hong YK; Lin YC; Lee YR; Tu WT; Papanikolaou M; Benzian-Olsson N; Onoufriadis A; I Chen Harn H; Hwang DY; Cheng SM; Lu K; Chen PC; McGrath JA; Hsu CK
    Br J Dermatol; 2024 Jul; 191(2):252-260. PubMed ID: 38477474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermolysis Bullosa Pruriginosa successfully treated with concomitant topical and systemic agents.
    Ferreira S; Azevedo A; Velho GC; Sanches M; Selores M
    Australas J Dermatol; 2020 Nov; 61(4):355-357. PubMed ID: 32524588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermolysis bullosa pruriginosa: A rare entity which responded well to thalidomide.
    Rani S; Gupta A; Bhardwaj M
    Dermatol Ther; 2019 Sep; 32(5):e13035. PubMed ID: 31355515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report.
    Wang Y; Zhou M; Zhang L; Zheng S; Hong Y; Gao XH
    Dermatol Ther; 2021 Nov; 34(6):e15130. PubMed ID: 34528352
    [No Abstract]   [Full Text] [Related]  

  • 8. Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab.
    Yu L; Wang J; Bian L; Li Z; Li M; Li J; Zhang S
    Dermatitis; 2023; 34(1):58-59. PubMed ID: 36705654
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab.
    Caroppo F; Milan E; Giulioni E; Belloni Fortina A
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e365-e367. PubMed ID: 34927769
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab.
    Shehadeh W; Sarig O; Bar J; Sprecher E; Samuelov L
    Br J Dermatol; 2020 Jun; 182(6):1495-1497. PubMed ID: 31899820
    [No Abstract]   [Full Text] [Related]  

  • 11. Epidermolysis bullosa pruriginosa masquerading as psychogenic pruritus.
    Tey HL; Lee AD; Almaani N; McGrath JA; Mills KC; Yosipovitch G
    Arch Dermatol; 2011 Aug; 147(8):956-60. PubMed ID: 21844455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Control of Recalcitrant Pruritus in Epidermolysis Bullosa Pruriginosa With Dupilumab.
    Roque Quintana B; Piqué Durán E; Pérez Cejudo JA
    Actas Dermosifiliogr; 2024 Feb; 115(2):184-186. PubMed ID: 36871818
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to 'A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab' by Caroppo et al.
    Martora F; Fabbrocini G; Nappa P; Marasca C; Patruno C; Scalvenzi M; Napolitano M
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e729-e730. PubMed ID: 35604042
    [No Abstract]   [Full Text] [Related]  

  • 14. Epidermolysis Bullosa Pruriginosa: Case Series and Review of the Literature.
    Kim WB; Alavi A; Pope E; Walsh S
    Int J Low Extrem Wounds; 2015 Jun; 14(2):196-9. PubMed ID: 25694436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa.
    Shao L; Zhong DQ; Liu YM; Wang JQ
    Int J Dermatol; 2023 Oct; 62(10):e542-e545. PubMed ID: 37326291
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of a novel COL7A1 variant associated with dystrophic epidermolysis bullosa pruriginosa responding effectively to dupilumab.
    Zhao C; Cao S; Gao X; Xu X; Gu L
    Mol Genet Genomic Med; 2023 Nov; 11(11):e2258. PubMed ID: 37676173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising effect of intravenous immunoglobulin therapy for epidermolysis bullosa pruriginosa.
    Ertop P; Vural S; Gökpınar Ili E; Durmaz CD; Heper AO; McGrath JA; Ilgın RH; Boyvat A
    Int J Dermatol; 2020 Jul; 59(7):851-855. PubMed ID: 32506551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coinheritance of 2 New Potentially Damaging Heterozygous COL7A1 Variants in a Family With Autosomal Dominant Epidermolysis Bullosa Pruriginosa.
    Hale GI; Cohen MC; Quarrell OW; McGrath JA; Messenger AG
    Pediatr Dev Pathol; 2018; 21(6):580-584. PubMed ID: 29504492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermolysis bullosa pruriginosa responding to dupilumab.
    Clawson RC; Duran SF; Pariser RJ
    JAAD Case Rep; 2021 Oct; 16():69-71. PubMed ID: 34522751
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidermolysis bullosa pruriginosa in association with lichen planopilaris.
    Almaani N; Liu L; Perez A; Robson A; Mellerio JE; McGrath JA
    Clin Exp Dermatol; 2009 Dec; 34(8):e825-8. PubMed ID: 20055845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.